

Brian Lee Claggett

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4414334/brian-lee-claggett-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

255
papers

13,643
citations

56
h-index

111
g-index

300
ext. papers

18,580
ext. citations

10
avg, IF

6.32
L-index

#	Paper	IF	Citations
255	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2015 , 373, 2247-57	59.2	1393
254	Spironolactone for heart failure with preserved ejection fraction. <i>New England Journal of Medicine</i> , 2014 , 370, 1383-92	59.2	1365
253	Angiotensin-Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1609-1620	59.2	705
252	Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. <i>Circulation</i> , 2015 , 131, 34-42	16.7	534
251	Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 447-56	15.1	439
250	Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2380-5	2.2	327
249	Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. <i>Lancet Public Health, The</i> , 2018 , 3, e419-e428	22.4	294
248	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation</i> , 2015 , 132, 402-14	16.7	263
247	Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. <i>European Heart Journal</i> , 2015 , 36, 1990-7	9.5	245
246	Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2016 , 37, 455-62	9.5	217
245	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2017 , 5, 333-340	18.1	164
244	Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018 , 20, 1230-1239	12.3	159
243	Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. <i>Circulation: Heart Failure</i> , 2014 , 7, 740-51	7.6	159
242	Impaired left atrial function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014 , 16, 1096-103	12.3	150
241	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016 , 9, e002763	7.6	147
240	Renal Effects and Associated Outcomes During Angiotensin-Nepriylsin Inhibition in Heart Failure. <i>JACC: Heart Failure</i> , 2018 , 6, 489-498	7.9	138
239	Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014 , 16, 535-42	12.3	137

238	The amyloidogenic V122I transthyretin variant in elderly black Americans. <i>New England Journal of Medicine</i> , 2015 , 372, 21-9	59.2	136
237	Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation. <i>New England Journal of Medicine</i> , 2017 , 376, 1690-1692	59.2	135
236	Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. <i>Annals of Internal Medicine</i> , 2015 , 163, 127-34	8	122
235	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Circulation</i> , 2020 , 141, 338-351	16.7	122
234	Retinal Vessel Calibers in Predicting Long-Term Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2016 , 134, 1328-1338	16.7	121
233	On the restricted mean survival time curve in survival analysis. <i>Biometrics</i> , 2016 , 72, 215-21	1.8	119
232	Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2016 , 18, 1228-1234	12.3	118
231	Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015 , 17, 510-7	12.3	115
230	Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. <i>JAMA Oncology</i> , 2017 , 3, 1692-1696	13.4	113
229	Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. <i>Circulation: Heart Failure</i> , 2014 , 7, 573-9	7.6	112
228	Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. <i>Circulation: Heart Failure</i> , 2016 , 9, e002744	7.6	100
227	Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2014 , 130, 820-8	16.7	100
226	Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. <i>Circulation: Heart Failure</i> , 2014 , 7, 590-5	7.6	97
225	Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort: The Atherosclerosis Risk in Communities-Sleep Heart Health Study. <i>Circulation</i> , 2015 , 132, 1329-37	16.7	94
224	Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. <i>JACC: Heart Failure</i> , 2017 , 5, 241-252	7.9	90
223	Machine learning-based phenotyping in heart failure to identify responders to cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2019 , 21, 74-85	12.3	90
222	Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 547-554	18.1	89
221	Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2016 , 1, 666-72	16.2	86

220	Heart Failure Stages Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2017 , 135, 224-240	16.7	86
219	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. <i>JAMA Cardiology</i> , 2017 , 2, 79-85	16.2	84
218	EFFECTIVELY SELECTING A TARGET POPULATION FOR A FUTURE COMPARATIVE STUDY. <i>Journal of the American Statistical Association</i> , 2013 , 108, 527-539	2.8	84
217	Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 795-806	15.1	82
216	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1264-1272	15.1	79
215	Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. <i>JACC: Heart Failure</i> , 2016 , 4, 152-158	7.9	73
214	Distinct neural representations of placebo and nocebo effects. <i>NeuroImage</i> , 2015 , 112, 197-207	7.9	73
213	Rationale, design, and baseline characteristics in Evaluation of Lixisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015 , 169, 631-638.e7	4.9	72
212	Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. <i>New England Journal of Medicine</i> , 2015 , 373, 2289-90	59.2	71
211	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 337-341	12.3	69
210	Influenza Vaccine in Heart Failure. <i>Circulation</i> , 2019 , 139, 575-586	16.7	67
209	Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. <i>Circulation</i> , 2020 , 142, 2080-2082	16.7	66
208	Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term Outcomes. <i>JACC: Heart Failure</i> , 2019 , 7, 849-858	7.9	65
207	Contemporary Assessment of Left Ventricular Diastolic Function in Older Adults: The Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2017 , 135, 426-439	16.7	63
206	Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. <i>European Heart Journal</i> , 2015 , 36, 939-45	9.5	62
205	Are all placebo effects equal? Placebo pills, sham acupuncture, cue conditioning and their association. <i>PLoS ONE</i> , 2013 , 8, e67485	3.7	62
204	Association of Influenza-like Illness Activity With Hospitalizations for Heart Failure: The Atherosclerosis Risk in Communities Study. <i>JAMA Cardiology</i> , 2019 , 4, 363-369	16.2	61
203	Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 1460-5	10.2	61

202	Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters. <i>Gastrointestinal Endoscopy</i> , 2011 , 73, 1174-80	5.2	60
201	Right Atrial Function in Pulmonary Arterial Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2015 , 8, e003521; discussion e003521	3.9	58
200	Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial. <i>JACC: Heart Failure</i> , 2016 , 4, 816-822	7.9	58
199	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. <i>European Journal of Heart Failure</i> , 2014 , 16, 671-7	12.3	56
198	The frailty syndrome and outcomes in the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 1570-1577	15.7	56
197	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). <i>Circulation</i> , 2017 , 136, 982-992	16.7	55
196	Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	55
195	Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2858-2873	15.1	55
194	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation: Heart Failure</i> , 2015 , 8, 1052-8	7.6	54
193	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2014 , 35, 3442-51	9.5	54
192	Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. <i>European Heart Journal</i> , 2012 , 33, 1137-41	9.5	54
191	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1199-1208	6.7	51
190	Left atrial structure and function in cardiac amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2017 , 18, 1128-1137	4.1	50
189	Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2014 , 35, 42-7	9.5	48
188	Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study. <i>Circulation: Heart Failure</i> , 2015 , 8, 448-54	7.6	47
187	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. <i>European Heart Journal</i> , 2015 , 36, 669-75	9.5	47
186	Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. <i>Circulation: Heart Failure</i> , 2016 , 9, e001937	7.6	47
185	Right Ventricular Function, Right Ventricular-Pulmonary Artery Coupling, and Heart Failure Risk in 4 US Communities: The Atherosclerosis Risk in Communities (ARIC) Study. <i>JAMA Cardiology</i> , 2018 , 3, 939-948	16.2	46

184	Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	45
183	Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. <i>European Journal of Heart Failure</i> , 2016 , 18, 1238-1243	12.3	44
182	Insulin resistance and incident heart failure the ARIC study (Atherosclerosis Risk in Communities). <i>JACC: Heart Failure</i> , 2013 , 1, 531-6	7.9	44
181	Association of Weight and Body Composition on Cardiac Structure and Function in the ARIC Study (Atherosclerosis Risk in Communities). <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	43
180	Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2016 , 374, 1095-6	59.2	42
179	Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study. <i>JAMA Cardiology</i> , 2019 , 4, 466-472	16.2	40
178	Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). <i>Gastrointestinal Endoscopy</i> , 2013 , 77, 624-30	5.2	40
177	Racial differences in circulating natriuretic peptide levels: the atherosclerosis risk in communities study. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	40
176	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1217-1225	12.3	39
175	Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly. <i>Circulation</i> , 2015 , 132, 1979-89	16.7	38
174	Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials. <i>Circulation</i> , 2018 , 138, 570-577	16.7	38
173	Smoking and Cardiac Structure and Function in the Elderly: The ARIC Study (Atherosclerosis Risk in Communities). <i>Circulation: Cardiovascular Imaging</i> , 2016 , 9, e004950	3.9	38
172	Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , 2015 , 17, 301-12	12.3	37
171	Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). <i>Circulation: Heart Failure</i> , 2018 , 11, e004448	7.6	37
170	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 504-510	12.3	37
169	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. <i>JACC: Heart Failure</i> , 2018 , 6, 689-697	7.9	36
168	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	35
167	Increased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel disease. <i>Clinical and Translational Gastroenterology</i> , 2012 , 3, e19	4.2	35

166	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). <i>Circulation: Heart Failure</i> , 2018, 11, 1040-1048	7.6	34
165	Prehypertension is Associated With Abnormalities of Cardiac Structure and Function in the Atherosclerosis Risk in Communities Study. <i>American Journal of Hypertension</i> , 2016, 29, 568-74	2.3	34
164	Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1763-1773	15.1	34
163	Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1701-1709	12.3	34
162	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 313-320	3.3	33
161	Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Diabetes Care</i> , 2016, 39, 677-85	14.6	32
160	Heart failure risk across the spectrum of ankle-brachial index: the ARIC study (Atherosclerosis Risk In Communities). <i>JACC: Heart Failure</i> , 2014, 2, 447-54	7.9	32
159	Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 1236-1245	16.7	32
158	Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. <i>JACC: Heart Failure</i> , 2019, 7, 25-32	7.9	32
157	Declining Lung Function and Cardiovascular Risk: The ARIC Study. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1109-1122	15.1	30
156	Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints. <i>Biostatistics</i> , 2015, 16, 60-72	3.7	30
155	Sex Differences in Blood Pressure Associations With Cardiovascular Outcomes. <i>Circulation</i> , 2021, 143, 761-763	16.7	30
154	Visualization, Quantification, and Alignment of Spectral Drift in Population Scale Untargeted Metabolomics Data. <i>Analytical Chemistry</i> , 2017, 89, 1399-1404	7.8	29
153	Left ventricular ejection time is an independent predictor of incident heart failure in a community-based cohort. <i>European Journal of Heart Failure</i> , 2018, 20, 1106-1114	12.3	29
152	Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021, 23, 1040-1048	12.3	29
151	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. <i>Circulation</i> , 2019, 140, 1369-1379	16.7	28
150	Relationship between alcohol consumption and cardiac structure and function in the elderly: the Atherosclerosis Risk In Communities Study. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8,	3.9	28
149	Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study. <i>JAMA Cardiology</i> , 2018, 3, 200-206	16.2	28

148	Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019 , 7, 664-675	7.9	28
147	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. <i>European Journal of Heart Failure</i> , 2017 , 19, 792-799	12.3	28
146	Lack of Association Between Heart Failure and Incident Cancer. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1501-1510	15.1	27
145	Race influences the safety and efficacy of spironolactone in severe heart failure. <i>Circulation: Heart Failure</i> , 2013 , 6, 970-6	7.6	27
144	An Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	26
143	A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies. <i>Biometrics</i> , 2016 , 72, 877-87	1.8	25
142	Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. <i>Circulation: Heart Failure</i> , 2014 , 7, 895-902	7.6	25
141	Race-Related Differences in Left Ventricular Structural and Functional Remodeling in Response to Increased Afterload: The ARIC Study. <i>JACC: Heart Failure</i> , 2017 , 5, 157-165	7.9	24
140	Ferritin levels and risk of heart failure-the Atherosclerosis Risk in Communities Study. <i>European Journal of Heart Failure</i> , 2017 , 19, 340-347	12.3	24
139	Influence of cigarette smoking on cardiac biomarkers: the Atherosclerosis Risk in Communities (ARIC) Study. <i>European Journal of Heart Failure</i> , 2016 , 18, 629-37	12.3	24
138	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018 , 11, e005288	7.6	23
137	Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 1043-1052	12.3	22
136	Adiposity, body composition and ventricular-arterial stiffness in the elderly: the Atherosclerosis Risk in Communities Study. <i>European Journal of Heart Failure</i> , 2018 , 20, 1191-1201	12.3	22
135	Infection and Malignancy Outweigh Cardiovascular Mortality in Kidney Transplant Recipients: Post Hoc Analysis of the FAVORIT Trial. <i>American Journal of Medicine</i> , 2018 , 131, 165-172	2.4	22
134	Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. <i>European Heart Journal</i> , 2016 , 37, 466-72	9.5	22
133	The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. <i>Journal of the American Society of Echocardiography</i> , 2016 , 29, 537-44	5.8	22
132	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 39-49	27.4	22
131	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2016 , 68, 873-881	7.4	21

130	Angiotensin Receptor-Nephrilysin Inhibition in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021 , 385, 1845-1855	59.2	21
129	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. <i>European Journal of Heart Failure</i> , 2019 , 21, 1571-1579	12.3	21
128	Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. <i>JAMA Cardiology</i> , 2019 , 4, 997-1006	16.2	20
127	Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Hypertension</i> , 2018 , 31, 407-414	2.3	20
126	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2018 , 11, e004457	7.6	20
125	Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2015 , 66, 429-40	7.4	20
124	Cardiac structure and function and leisure-time physical activity in the elderly: The Atherosclerosis Risk in Communities Study. <i>European Heart Journal</i> , 2016 , 37, 2544-51	9.5	20
123	Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy. <i>Heart</i> , 2019 , 105, 34-41	5.1	19
122	Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. <i>Journal of Heart and Lung Transplantation</i> , 2014 , 33, 372-81	5.8	19
121	Regional Longitudinal Deformation Improves Prediction of Ventricular Tachyarrhythmias in Patients With Heart Failure With Reduced Ejection Fraction: A MADIT-CRT Substudy (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). <i>Circulation: Cardiovascular Imaging</i> , 2017 , 10,	3.9	18
120	Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study. <i>JACC: Heart Failure</i> , 2017 , 5, 782-791	7.9	18
119	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. <i>JACC: Heart Failure</i> , 2018 , 6, 564-569	7.9	18
118	Trajectories of Blood Pressure Elevation Preceding Hypertension Onset: An Analysis of the Framingham Heart Study Original Cohort. <i>JAMA Cardiology</i> , 2018 , 3, 427-431	16.2	18
117	Left Atrial Structure and Function Across the Spectrum of Cardiovascular Risk in the Elderly: The Atherosclerosis Risk in Communities Study. <i>Circulation: Cardiovascular Imaging</i> , 2016 , 9, e004010	3.9	18
116	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. <i>JACC: Heart Failure</i> , 2020 , 8, 844-855	7.9	18
115	Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 1662-1671	12.3	17
114	Meta-Analysis With Fixed, Unknown, Study-Specific Parameters. <i>Journal of the American Statistical Association</i> , 2014 , 109, 1660-1671	2.8	17
113	A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves. <i>Statistics in Medicine</i> , 2015 , 34, 3680-95	2.3	17

112	Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>Journal of the American Heart Association</i> , 2016 , 5,	6	17
111	Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 483-490	12.3	17
110	Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension. <i>European Journal of Heart Failure</i> , 2015 , 17, 63-73	12.3	16
109	Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks. <i>JAMA Cardiology</i> , 2018 , 3, 357-358	16.2	16
108	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. <i>Circulation</i> , 2018 , 138, 1599-1601	16.7	16
107	IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2018 , 11, e005133	7.6	16
106	Longitudinal Associations Between Income Changes and Incident Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. <i>JAMA Cardiology</i> , 2019 , 4, 1203-1212	16.2	15
105	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2019 , 73, 309-315	7.4	15
104	Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). <i>American Journal of Cardiology</i> , 2019 , 123, 611-617	3	14
103	Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018 , 11, 155-164	2.5	13
102	Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. <i>Journal of Diabetes Research</i> , 2018 , 2018, 1631263	3.9	13
101	Caffeine Consumption and Mortality in Diabetes: An Analysis of NHANES 1999-2010. <i>Frontiers in Endocrinology</i> , 2018 , 9, 547	5.7	13
100	Racial Disparities in Risks of Stroke. <i>New England Journal of Medicine</i> , 2017 , 376, 2089-2090	59.2	12
99	Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 315-322	4.6	11
98	Widening Racial Differences in Risks for Coronary Heart Disease. <i>Circulation</i> , 2018 , 137, 1195-1197	16.7	11
97	The 3A3B score: The simple risk score for heart failure with preserved ejection fraction - A report from the CHART-2 Study. <i>International Journal of Cardiology</i> , 2019 , 284, 42-49	3.2	11
96	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019 , 12, e006125	7.6	10
95	Body mass index and B-lines on lung ultrasonography in chronic and acute heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 1201-1209	3.7	10

94	A Pilot Study of Confocal Laser Endomicroscopy to Predict Barrier Dysfunction and Relapse in Pediatric Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016 , 62, 873-88	2.8	10
93	Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry. <i>European Journal of Heart Failure</i> , 2019 , 21, 1129-1141	12.3	10
92	Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits. <i>JACC: Heart Failure</i> , 2017 , 5, 591-599	7.9	10
91	Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. <i>JACC: Heart Failure</i> , 2021 , 9, 13-24	7.9	10
90	Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. <i>Diabetologia</i> , 2018 , 61, 581-588	10.3	10
89	Differential influence of distinct components of increased blood pressure on cardiovascular outcomes: from the atherosclerosis risk in communities study. <i>Hypertension</i> , 2013 , 62, 492-8	8.5	9
88	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 ,	16.2	9
87	Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort Study. <i>Diabetes Care</i> , 2020 , 43, 2226-2233	14.6	9
86	Association of Undifferentiated Dyspnea in Late Life With Cardiovascular and Noncardiovascular Dysfunction: A Cross-sectional Analysis From the ARIC Study. <i>JAMA Network Open</i> , 2019 , 2, e195321	10.4	8
85	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. <i>European Journal of Heart Failure</i> , 2020 , 22, 1133-1143	12.3	8
84	ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2017 , 70, 522-531	7.4	7
83	Quantifying the totality of treatment effect with multiple event-time observations in the presence of a terminal event from a comparative clinical study. <i>Statistics in Medicine</i> , 2018 , 37, 3589-3598	2.3	7
82	Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life. <i>JAMA Cardiology</i> , 2021 , 6, 509-520	16.2	7
81	Epithelial Cell Extrusion Zones Observed on Confocal Laser Endomicroscopy Correlates with Immunohistochemical Staining of Mucosal Biopsy Samples. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1895-902	4	7
80	Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2021 , 77, 546-556	8.5	7
79	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.. <i>Circulation</i> , 2022 ,	16.7	7
78	The Myth of Making Inferences for an Overall Treatment Efficacy with Data from Multiple Comparative Studies Via Meta-Analysis. <i>Statistics in Biosciences</i> , 2017 , 9, 284-297	1.5	6
77	Efficacy of LCZ696 Persists at Lower Than Target Doses in the PARADIGM-HF Trial. <i>Journal of Cardiac Failure</i> , 2015 , 21, S9-S10	3.3	6

76	Associations Between Depressive Symptoms and HFpEF-Related Outcomes. <i>JACC: Heart Failure</i> , 2020 , 8, 1009-1020	7.9	6
75	Catheter ablation for atrial fibrillation is associated with lower incidence of heart failure and death. <i>Europace</i> , 2020 , 22, 74-83	3.9	6
74	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017 , 136, 1560-1562	16.7	5
73	Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1554-1561	4.5	5
72	Hypertonic Mannitol for the Prevention of Intradialytic Hypotension: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2019 , 74, 483-490	7.4	5
71	Mid- to Late-Life Time-Averaged Cumulative Blood Pressure and Late-Life Cardiac Structure, Function, and Heart Failure. <i>Hypertension</i> , 2020 , 76, 808-818	8.5	5
70	Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 815-816	12.3	5
69	Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. <i>American Journal of Nephrology</i> , 2017 , 46, 488-497	4.6	5
68	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2021 ,	16.7	5
67	Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans. <i>European Journal of Heart Failure</i> , 2021 , 23, 1290-1295	12.3	5
66	Prognostic Value of Natriuretic Peptides and Cardiac Troponins in COVID-19. <i>Circulation</i> , 2021 , 144, 177-189	16.9	5
65	Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association. <i>Circulation</i> , 2021 , 144, e70-e91	16.7	5
64	Towards personalized therapy for multiple sclerosis: limitations of observational data. <i>Brain</i> , 2018 , 141, e38	11.2	4
63	Defining Study Outcomes That Better Reflect Individual Response to Treatment. <i>Pediatric Infectious Disease Journal</i> , 2018 , 37, 258-262	3.4	4
62	Assessing Treatment Effects That Capture Disease Burden in Serious Chronic Diseases. <i>Therapeutic Innovation and Regulatory Science</i> , 2019 , 53, 387-397	1.2	4
61	Postsystolic shortening on echocardiography as a gateway to cardiac computed tomography in patients with suspected stable angina pectoris. <i>International Journal of Cardiovascular Imaging</i> , 2020 , 36, 309-316	2.5	4
60	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. <i>Circulation: Heart Failure</i> , 2021 , 14, e008052	7.6	4
59	The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). <i>European Journal of Heart Failure</i> , 2021 , 23, 1052-1056	12.3	4

58	Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1638-1645	0.7	4
57	Excess mortality in solid organ transplant recipients hospitalized with COVID-19: A large-scale comparison of SOT recipients hospitalized with or without COVID-19. <i>Clinical Transplantation</i> , 2021 , e14492	3.8	4
56	Quantification of pleural effusions on thoracic ultrasound in acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 513-521	4.3	3
55	Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018 , 11, 1-7	2.5	3
54	Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial. <i>International Journal of Nephrology and Renovascular Disease</i> , 2017 , 10, 233-242	2.5	3
53	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis. <i>PLoS Medicine</i> , 2020 , 17, e1003361	11.6	3
52	Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex. <i>Circulation: Heart Failure</i> , 2021 , 14, e007891	7.6	3
51	Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021 , 10, e019545	6	3
50	Phase 3 Study of L-Glutamine in Sickle Cell Disease: Analyses of Time to First and Second Crisis and Average Cumulative Recurrent Events. <i>Blood</i> , 2017 , 130, 685-685	2.2	2
49	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021 , 14, e008293	7.6	2
48	Impact on survival of combination inhalers in patients with COPD at high risk of cardiovascular events. <i>International Journal of Cardiology</i> , 2020 , 300, 237-244	3.2	2
47	Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 386-397	7.9	2
46	A-lines and B-lines in patients with acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 909-917	4.3	2
45	Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	2
44	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1298-1305	16.2	2
43	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. <i>JACC: Heart Failure</i> , 2019 , 7, 1022-1028	7.9	2
42	HFE H63D Polymorphism and the Risk for Systemic Hypertension, Myocardial Remodeling, and Adverse Cardiovascular Events in the ARIC Study. <i>Hypertension</i> , 2019 , 73, 68-74	8.5	2
41	Sex differences in congestive markers in patients hospitalized for acute heart failure. <i>ESC Heart Failure</i> , 2021 , 8, 1784-1795	3.7	2

40	Atrial Fibrillation and Ischemic Stroke With the Amyloidogenic V122I Transthyretin Variant Among Black Americans. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 89-91	15.1	2
39	Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis. <i>BMJ Open</i> , 2022 , 12, e059994	3	2
38	Unifying Design and Analysis for Superiority and Noninferiority Trials With Appropriate End Point. <i>JAMA Surgery</i> , 2019 , 154, 466-467	5.4	1
37	When the VEST Does Not Fit: Representations of Trial Results Deviating From Rigorous Data Interpretation. <i>Circulation: Heart Failure</i> , 2018 , 11, e005116	7.6	1
36	Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma. <i>JAMA Oncology</i> , 2018 , 4, 1617-1618	13.4	1
35	Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart Failure.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 355-368	15.1	1
34	Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.. <i>JACC: Heart Failure</i> , 2022 , 10, 119-128	7.9	1
33	Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies. <i>Statistics in Medicine</i> , 2021 , 40, 6235-6242	2.3	1
32	Depressive Symptoms, Cardiac Structure and Function, and Risk of Incident Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction in Late Life. <i>Journal of the American Heart Association</i> , 2021 , 10, e020094	6	1
31	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. <i>Cardiovascular Diabetology</i> , 2020 , 19, 175	8.7	1
30	Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial. <i>Circulation: Heart Failure</i> , 2020 , 13, e008007	7.6	1
29	Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1211-1221	15.1	1
28	Temporal variations in the severity of COVID-19 illness by race and ethnicity. <i>BMJ Nutrition, Prevention and Health</i> , 2021 , 4, 166-173	6.7	1
27	Heart failure associated with imported malaria: a nationwide Danish cohort study. <i>ESC Heart Failure</i> , 2021 , 8, 3521-3529	3.7	1
26	Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 677-685	4.5	1
25	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 627-635	7.9	1
24	Cardiac Structure and Function and Diabetes-Related Risk of Death or Heart Failure in Older Adults.. <i>Journal of the American Heart Association</i> , 2022 , e022308	6	1
23	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes.. <i>Journal of the American Heart Association</i> , 2022 , e021327	6	1

22	Association of Left Atrial Structure and Function With Heart Failure in Older Adults.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1549-1561	15.1	1
21	The Reply. <i>American Journal of Medicine</i> , 2018 , 131, e349-e351	2.4	0
20	Sex as a predictor of response to cancer immunotherapy. <i>Lancet Oncology</i> , 2018 , 19, e377	21.7	0
19	Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort Study.. <i>Journal of the American Heart Association</i> , 2022 , e021715	6	0
18	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021 , 10, e021494	6	0
17	Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1382-1392	3.3	0
16	Combining diastolic dysfunction and natriuretic peptides to risk stratify patients with heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2021 , 335, 59-65	3.2	0
15	Associations of Insulin Resistance With Systolic and Diastolic Blood Pressure: A Study From the HCHS/SOL. <i>Hypertension</i> , 2021 , 78, 716-725	8.5	0
14	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 336-346	7.9	0
13	Left Atrial Remodeling and Stroke in Patients With Sinus Rhythm and Normal Ejection Fraction: ARIC-NCS.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024292	6	0
12	Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF?. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1535-6	15.1	
11	Sacubitril/valsartan in PARADIGM-HF - Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 496	18.1	
10	Response to Letter Regarding Article, Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study. <i>Circulation: Heart Failure</i> , 2015 , 8, 1010	7.6	
9	Reply from the authors. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 869-70	10.2	
8	Myocardial performance index is associated with cardiac computed tomography findings in patients with suspected coronary artery disease. <i>Echocardiography</i> , 2020 , 37, 1741-1748	1.5	
7	Response by Claggett et al to Letter Regarding Article, "Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials". <i>Circulation</i> , 2019 , 139, 422-423	16.7	
6	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis 2020 , 17, e1003361		
5	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis 2020 , 17, e1003361		

- 4 Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis **2020**, 17, e1003361
- 3 Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis **2020**, 17, e1003361
- 2 Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis **2020**, 17, e1003361
- 1 Left atrial inflow propagation velocity derived by color M-mode Doppler in acute heart failure. *International Journal of Cardiovascular Imaging*,1